Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.

La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, Russello D.

World J Gastroenterol. 2012 Aug 21;18(31):4150-5. doi: 10.3748/wjg.v18.i31.4150.

2.

CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.

Morris-Stiff G, Teli M, Jardine N, Puntis MC.

Hepatobiliary Pancreat Dis Int. 2009 Dec;8(6):620-6.

PMID:
20007080
3.

CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F.

Am J Surg. 2009 Sep;198(3):333-9. doi: 10.1016/j.amjsurg.2008.12.031. Epub 2009 Apr 17.

PMID:
19375064
4.

Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.

Mann DV, Edwards R, Ho S, Lau WY, Glazer G.

Eur J Surg Oncol. 2000 Aug;26(5):474-9.

PMID:
11016469
5.

FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Wannhoff A, Hov JR, Folseraas T, Rupp C, Friedrich K, Anmarkrud JA, Weiss KH, Sauer P, Schirmacher P, Boberg KM, Stremmel W, Karlsen TH, Gotthardt DN.

J Hepatol. 2013 Dec;59(6):1278-84. doi: 10.1016/j.jhep.2013.08.005. Epub 2013 Aug 16.

PMID:
23958938
6.

Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.

Connor S, Bosonnet L, Alexakis N, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP.

Dig Surg. 2005;22(1-2):80-5. Epub 2005 Apr 20.

PMID:
15849467
7.

Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis.

Beyazit Y, Kekilli M, Ibis M, Kurt M, Sayilir A, Onal IK, Purnak T, Oztas E, Tas A, Yesil Y, Arhan M.

Hepatogastroenterology. 2012 Jul-Aug;59(117):1469-73. doi: 10.5754/hge10676.

PMID:
22683963
8.

The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.

Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A.

Dig Dis Sci. 2011 Aug;56(8):2491-6. doi: 10.1007/s10620-011-1709-8. Epub 2011 Apr 23.

PMID:
21516323
9.

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.

Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.

Eur J Surg Oncol. 2005 Mar;31(2):164-9.

PMID:
15698733
10.

CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.

Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA.

Liver Transpl Surg. 1995 Mar;1(2):94-8.

11.

Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.

Ince AT, Yıldız K, Baysal B, Danalıoğlu A, Kocaman O, Tozlu M, Gangarapu V, Sarbay Kemik A, Uysal Ö, Şentürk H.

Turk J Gastroenterol. 2014 Apr;25(2):162-9. doi: 10.5152/tjg.2014.6056.

12.

[CA19-9 has no value as a tumor marker in obstructive jaundice].

Peterli R, Meyer-Wyss B, Herzog U, Tondelli P.

Schweiz Med Wochenschr. 1999 Jan 23;129(3):77-9. Review. German.

PMID:
10065510
13.

Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.

Li YG, Zhang N.

Dig Liver Dis. 2009 Aug;41(8):605-8. doi: 10.1016/j.dld.2008.11.010. Epub 2009 Jan 24.

PMID:
19168405
14.

Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.

Ng WW, Tong KJ, Tam TN, Lee SD.

Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jun;55(6):438-46.

PMID:
7634181
15.

Mucin-producing cholangiocarcinoma: clinical experience of 24 cases in 16 years.

Kuo CM, Changchien CS, Wu KL, Chuah SK, Chiu KW, Chiu YC, Chou YP, Kuo CH.

Scand J Gastroenterol. 2005 Apr;40(4):455-9.

PMID:
16028441
16.

Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.

Leelawat K, Sakchinabut S, Narong S, Wannaprasert J.

BMC Gastroenterol. 2009 Apr 30;9:30. doi: 10.1186/1471-230X-9-30.

17.

C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma.

Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL.

World J Gastroenterol. 2006 Sep 14;12(34):5495-500.

18.

[The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].

Zong D, Zeng Y.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 Sep;45(5):819-22. Chinese.

PMID:
25341348
19.

Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.

Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P 2nd.

Pancreas. 2006 Oct;33(3):246-9.

PMID:
17003645
20.

A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.

Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI.

Am J Gastroenterol. 1999 Jul;94(7):1941-6.

PMID:
10406263

Supplemental Content

Support Center